• The specific situation of the patient. Unless otherwise provided for by national regulations,
off-label use of medication should be limited to situations where it is in the patient's interest …

Remarkable recent advances have revolutionized the field of heart failure. Survival has
improved among individuals with heart failure and a reduced ejection fraction and for the …

Episodes of worsening symptoms and signs characterize the clinical course of patients with
chronic heart failure (HF). These events are associated with poorer quality of life, increased …

Acute heart failure is a major cause of urgent hospitalizations. These are followed by marked
increases in death and rehospitalization rates, which then decline exponentially though they …

Background Heart failure (HF) readmission rates are low in some jurisdictions. However,
international comparisons are lacking and could serve as a foundation for identifying …

Multiple landmark trials have helped to advance the treatment of heart failure with reduced
ejection fraction (HFrEF) significantly over the past decade. These trials have led to the …

Hospital at home (HaH) is an innovative care model that may be particularly suited for heart
failure (HF). Outpatient visits and inpatient care have been the 2 traditional settings for HF …

Abstract Document Reviewers: Rudolf A. de Boer (CPG Review Co‐ordinator)(Netherlands),
P. Christian Schulze (CPG Review Co‐ordinator)(Germany), Elena Arbelo (Spain), Jozef …

Natriuretic peptides (NPs) are the principal expression products of the endocrine function of
the heart. They exert several beneficial effects, mostly mediated through guanylate cyclase …

In the 1990s, 5-year new-onset heart failure (HF) survival was as low as 25%. The standard
treatment was fluid restriction, cardiac glycosides, and a combination of diuretics …